Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Cardiovascular Diabetology
Published in: Cardiovascular Diabetology 1/2023

Open Access 01-12-2023 | Heart Failure | Research

Triglyceride-glucose index and heart failure: a systematic review and meta-analysis

Authors: Amirmohammad Khalaji, Amir Hossein Behnoush, Shaghayegh Khanmohammadi, Kimiya Ghanbari Mardasi, Sourena Sharifkashani, Amirhossein Sahebkar, Caterina Vinciguerra, Alessandro Cannavo

Published in: Cardiovascular Diabetology | Issue 1/2023

Login to get access

Abstract

Background

Insulin resistance (IR) is a major metabolic disorder observed in heart failure (HF) and is tightly associated with patients’ poor prognosis. The triglyceride-glucose index (TyG) has been proposed as a surrogate marker of IR in HF. Yet, whether TyG is a reliable clinical marker is still under debate. Hence, we aimed to respond to this relevant question via a systematic review and meta-analysis of existing studies.

Methods

A systematic search was conducted in PubMed, Embase, Scopus, and Web of Science to find studies investigating the TyG index in patients with HF or its association with the incidence of HF. Adjusted hazard ratios (HR) and 95% confidence intervals (CI) were pooled through random-effect meta-analysis. HRs were calculated using TyG as a continuous variable (1 unit increase) and by comparing the group with the highest TyG to the lowest TyG group.

Results

Thirty studies, involving 772,809 participants, were included in this systematic review. Meta-analysis of seven studies comparing the highest-TyG to the lowest-TyG group showed a significantly increased risk of HF in the former group (HR 1.21, 95% CI 1.14 to 1.29, P < 0.01). The same result was found when pooling the HRs for a one-unit increase in the TyG index (HR 1.17, 95% CI 1.08 to 1.26). Similarly, a more elevated TyG index was associated with a higher incidence of HF in patients with type 2 diabetes or coronary artery disease. Additionally, the incidence of adverse events (readmission and mortality) in patients with HF was associated with TyG.

Conclusion

Our findings support the TyG index as a valuable marker to assess the risk of HF incidence in different populations and as a prognostic marker in patients with HF. Further studies should be conducted to confirm these associations and investigate the clinical utility of the TyG index.
Appendix
Available only for authorised users
Literature
1.
Filippatos G, Khan SS, Ambrosy AP, Cleland JG, Collins SP, Lam CS, et al. International REgistry to assess medical practice with lOngitudinal obseRvation for treatment of heart failure (REPORT-HF): rationale for and design of a global registry. Eur J Heart Fail. 2015;17(5):527–33.PubMedCrossRef
2.
Murphy SP, Ibrahim NE, Januzzi JL. Jr. Heart failure with reduced ejection fraction: a review. JAMA. 2020;324(5):488–504.PubMedCrossRef
3.
Behnoush AH, Khalaji A, Naderi N, Ashraf H, von Haehling S. ACC/AHA/HFSA 2022 and ESC 2021 guidelines on heart failure comparison. ESC Heart Fail. 2023;10(3):1531–44.PubMedCrossRef
4.
Ciccarelli M, Chuprun JK, Rengo G, Gao E, Wei Z, Peroutka RJ, et al. G protein-coupled receptor kinase 2 activity impairs cardiac glucose uptake and promotes insulin resistance after myocardial ischemia. Circulation. 2011;123(18):1953–62.PubMedPubMedCentralCrossRef
5.
Witteles RM, Fowler MB. Insulin-resistant cardiomyopathy clinical evidence, mechanisms, and treatment options. J Am Coll Cardiol. 2008;51(2):93–102.PubMedCrossRef
6.
Campbell P, Krim S, Ventura H. The bi-directional impact of two chronic illnesses: heart failure and diabetes - A review of the epidemiology and outcomes. Card Fail Rev. 2015;1(1):8–10.PubMedPubMedCentralCrossRef
7.
Banerjee D, Biggs ML, Mercer L, Mukamal K, Kaplan R, Barzilay J, et al. Insulin resistance and risk of incident heart failure: Cardiovascular Health Study. Circ Heart Fail. 2013;6(3):364–70.PubMedPubMedCentralCrossRef
8.
Muniyappa R, Lee S, Chen H, Quon MJ. Current approaches for assessing insulin sensitivity and resistance in vivo: advantages, limitations, and appropriate usage. Am J Physiol Endocrinol Metab. 2008;294(1):E15–26.PubMedCrossRef
9.
Li X, Wang J, Niu L, Tan Z, Ma J, He L, et al. Prevalence estimates of the insulin resistance and associated prevalence of heart failure among United Status adults. BMC Cardiovasc Disord. 2023;23(1):294.PubMedPubMedCentralCrossRef
10.
Wang L, Cong HL, Zhang JX, Hu YC, Wei A, Zhang YY, et al. Triglyceride-glucose index predicts adverse cardiovascular events in patients with diabetes and acute coronary syndrome. Cardiovasc Diabetol. 2020;19(1):80.PubMedPubMedCentralCrossRef
11.
Li H, Zuo Y, Qian F, Chen S, Tian X, Wang P, et al. Triglyceride-glucose index variability and incident cardiovascular disease: a prospective cohort study. Cardiovasc Diabetol. 2022;21(1):105.PubMedPubMedCentralCrossRef
12.
Zhao Q, Zhang TY, Cheng YJ, Ma Y, Xu YK, Yang JQ, et al. Impacts of triglyceride-glucose index on prognosis of patients with type 2 diabetes mellitus and non-ST-segment elevation acute coronary syndrome: results from an observational cohort study in China. Cardiovasc Diabetol. 2020;19(1):108.PubMedPubMedCentralCrossRef
13.
Guo WQ, Zhao LY, Mo FR, Peng CN, Li L, Xu Y, et al. The prognostic value of the triglyceride glucose index in patients with chronic heart failure and type 2 diabetes: a retrospective cohort study. Diabetes Res Clin Pract. 2021;177:108786.PubMedCrossRef
14.
Huang R, Lin Y, Ye X, Zhong X, Xie P, Li M, et al. Triglyceride-glucose index in the development of heart failure and left ventricular dysfunction: analysis of the ARIC study. Eur J Prev Cardiol. 2022;29(11):1531–41.PubMedCrossRef
15.
Xu L, Wu M, Chen S, Yang Y, Wang Y, Wu S, et al. Triglyceride-glucose index associates with incident heart failure: a cohort study. Diabetes Metab. 2022;48(6):101365.PubMedCrossRef
16.
Yang S, Du Y, Liu Z, Zhang R, Lin X, Ouyang Y, et al. Triglyceride-glucose index and extracellular volume fraction in patients with heart failure. Front Cardiovasc Med. 2021;8:704462.PubMedPubMedCentralCrossRef
17.
18.
Sun T, Huang X, Zhang B, Ma M, Chen Z, Zhao Z, et al. Prognostic significance of the triglyceride-glucose index for patients with ischemic heart failure after percutaneous coronary intervention. Front Endocrinol  2023;14:1100399.CrossRef
19.
Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372:n71.PubMedPubMedCentralCrossRef
20.
21.
Higgins JP, Green S. Cochrane handbook for systematic reviews of interventions. John Wiley Sons Ltd: Hoboken; 2008.CrossRef
22.
23.
Higgins JP, Altman DG, Gøtzsche PC, Jüni P, Moher D, Oxman AD, et al. The Cochrane collaboration’s tool for assessing risk of bias in randomised trials. BMJ. 2011;343:d5928.PubMedPubMedCentralCrossRef
24.
Abuduaini B, Yang L, Jiamali N, Seyiti Z, Shan XF, Gao XM. Predictive effect of triglyceride-glucose index on adverse prognostic events in patients with type 2 diabetes Mellitus and ischemic cardiomyopathy. Diabetes Metab Syndr Obes. 2023;16:1093–107.PubMedPubMedCentralCrossRef
25.
Al-Ali SA, Alidrisi HA, Hameed A. Correlation of insulin resistance with short-term outcome in nondiabetic patients with ST-Segment Elevation myocardial infarction. Cureus. 2022;14(12):e33093.PubMedPubMedCentral
26.
Chen YY, Fu JF, Wang Y, Zhang Y, Shi M, Wang C, et al. Association between triglyceride glucose index and subclinical left ventricular systolic dysfunction in patients with type 2 diabetes. Lipids Health Dis. 2023;22(1):1–9.CrossRef
27.
Chiu TH, Tsai HJ, Chiou HYC, Wu PY, Huang JC, Chen SC. A high triglyceride-glucose index is associated with left ventricular dysfunction and atherosclerosis. Int J Med Sci. 2021;18(4):1051–7.PubMedPubMedCentralCrossRef
28.
Gao S, Ma W, Huang S, Lin X, Yu M. Impact of triglyceride-glucose index on long-term cardiovascular outcomes in patients with myocardial infarction with nonobstructive coronary arteries. Nutr Metab Cardiovasc Dis. 2021;31(11):3184–92.PubMedCrossRef
29.
Han S, Wang C, Tong F, Li Y, Li Z, Sun Z, et al. Triglyceride glucose index and its combination with the get with the Guidelines-Heart failure score in predicting the prognosis in patients with heart failure. Front Nutr. 2022;9:950338.PubMedPubMedCentralCrossRef
30.
Huang HZ, Li Q, Liu JL, Qiao LF, Chen SQ, Lai WU, et al. Association between triglyceride glucose index and worsening heart failure in significant secondary mitral regurgitation following percutaneous coronary intervention. Cardiovasc Diabetol. 2022;21(1):260.PubMedPubMedCentralCrossRef
31.
Huang R, Wang ZY, Chen JZ, Bao X, Xu NJ, Guo SM, et al. Prognostic value of triglyceride glucose (TyG) index in patients with acute decompensated heart failure. Cardiovasc Diabetol. 2022;21(1):1.CrossRef
32.
Jung MH, Yi SW, An SJ, Yi JJ, Ihm SH, Han S, et al. Associations between the triglyceride-glucose index and cardiovascular disease in over 150,000 cancer survivors: a population-based cohort study. Cardiovasc Diabetol. 2022;21(1):52.PubMedPubMedCentralCrossRef
33.
Li X, Chan JSK, Guan B, Peng S, Wu X, Lu X, et al. Triglyceride-glucose index and the risk of heart failure: evidence from two large cohorts and a mendelian randomization analysis. Cardiovasc Diabetol. 2022;21(1):229.PubMedPubMedCentralCrossRef
34.
Liao LP, Yang Y, Wu Y, Li W. Correlation analysis of the triglyceride glucose index and heart failure with preserved ejection fraction in essential hypertensive patients. Clin Cardiol. 2022;45(9):936–42.PubMedPubMedCentralCrossRef
35.
Mao Q, Zhou D, Li Y, Wang Y, Xu SC, Zhao XH. The triglyceride-glucose index predicts coronary artery Disease Severity and Cardiovascular Outcomes in patients with Non-ST-Segment elevation Acute Coronary Syndrome. Dis Markers. 2019;2019:6891537.PubMedPubMedCentralCrossRef
36.
Muhammad IF, Bao X, Nilsson PM, Zaigham S. Triglyceride-glucose (TyG) index is a predictor of arterial stiffness, incidence of diabetes, cardiovascular disease, and all-cause and cardiovascular mortality: a longitudinal two-cohort analysis. Front Cardiovasc Med. 2022;9:1035105.PubMedCrossRef
37.
Sanlialp S, Nar G. The role of triglyceride glucose index in predicting in-hospital adverse cardiovascular outcomes in patients with acute coronary syndrome. J Exp Clin Med. 2021;38(4):583–8.CrossRef
38.
Sanlialp SC, Nar G, Gunver MG. Elevated triglyceride glucose index is related, to the presence of heart failure. J Istanb Fac Med-Istanb Tip Fak Derg. 2021;85:51.CrossRef
39.
Shi L, Liu J, Zhu X, Li T, Wen J, Wang X, et al. Triglyceride glucose index was a predictor of 6-Month Readmission caused by pulmonary infection of heart failure patients. Int J Endocrinol. 2022;2022:1131696.PubMedPubMedCentralCrossRef
40.
Si S, Li J, Li Y, Li W, Chen X, Yuan T, et al. Causal effect of the triglyceride-glucose index and the joint exposure of higher glucose and triglyceride with extensive cardio-cerebrovascular metabolic outcomes in the UK Biobank: a mendelian randomization study. Front Cardiovasc Med. 2020;7:583473.PubMedCrossRef
41.
42.
Tai S, Fu L, Zhang N, Zhou Y, Xing Z, Wang Y. Impact of baseline and trajectory of triglyceride-glucose index on cardiovascular outcomes in patients with type 2 diabetes mellitus. Front Endocrinol. 2022;13:858209.CrossRef
43.
Wang J, Huang X, Fu C, Sheng Q, Liu P. Association between triglyceride glucose index, coronary artery calcification and multivessel coronary disease in chinese patients with acute coronary syndrome. Cardiovasc Diabetol. 2022;21(1):187.PubMedPubMedCentralCrossRef
44.
Wang T, Xu J, Zhang H, Tao L, Huang X. Triglyceride-glucose index for the detection of subclinical heart failure with preserved ejection fraction in patients with type 2 diabetes. Front Cardiovasc Med. 2023;10:1086978.PubMedPubMedCentralCrossRef
45.
Zeng X, Han D, Zhou H, Xue Y, Wang X, Zhan Q, et al. Triglyceride-glucose index and Homeostasis Model Assessment-Insulin resistance in Young Adulthood and Risk of Incident Congestive Heart failure in midlife: the coronary artery risk development in young adults study. Front Cardiovasc Med. 2022;9:944258.PubMedPubMedCentralCrossRef
46.
Zhang H, Chong H, Li Z, Li K, Zhang B, Xue Y, et al. Triglyceride – glucose index in the prediction of major adverse cardiovascular events in patients with type 2 diabetes mellitus after coronary artery bypass surgery: a retrospective cohort study. Front Endocrinol. 2022;13:1015747.CrossRef
47.
Virani SS, Alonso A, Aparicio HJ, Benjamin EJ, Bittencourt MS, Callaway CW, et al. Heart Disease and Stroke Statistics-2021 update: a Report from the American Heart Association. Circulation. 2021;143(8):e254–e743.PubMedCrossRef
48.
Rahimi K, Bennett D, Conrad N, Williams TM, Basu J, Dwight J, et al. Risk prediction in patients with heart failure: a systematic review and analysis. JACC Heart Fail. 2014;2(5):440–6.PubMedCrossRef
49.
Roger VL. Epidemiology of Heart failure: a contemporary perspective. Circ Res. 2021;128(10):1421–34.PubMedCrossRef
50.
Ingelsson E, Sundström J, Arnlöv J, Zethelius B, Lind L. Insulin resistance and risk of congestive heart failure. JAMA. 2005;294(3):334–41.PubMedCrossRef
51.
Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia. 1985;28(7):412–9.PubMedCrossRef
52.
Simental-Mendía LE, Rodríguez-Morán M, Guerrero-Romero F. The product of fasting glucose and triglycerides as surrogate for identifying insulin resistance in apparently healthy subjects. Metab Syndr Relat Disord. 2008;6(4):299–304.PubMedCrossRef
53.
Vasques AC, Novaes FS, de Oliveira Mda S, Souza JR, Yamanaka A, Pareja JC, et al. TyG index performs better than HOMA in a brazilian population: a hyperglycemic clamp validated study. Diabetes Res Clin Pract. 2011;93(3):e98–e100.PubMedCrossRef
54.
Kang ES, Yun YS, Park SW, Kim HJ, Ahn CW, Song YD, et al. Limitation of the validity of the homeostasis model assessment as an index of insulin resistance in Korea. Metabolism. 2005;54(2):206–11.PubMedCrossRef
55.
Son D-H, Lee HS, Lee Y-J, Lee J-H, Han J-H. Comparison of triglyceride-glucose index and HOMA-IR for predicting prevalence and incidence of metabolic syndrome. Nutr Metabolism Cardiovasc Dis. 2022;32(3):596–604.CrossRef
56.
Luo P, Cao Y, Li P, Li W, Song Z, Fu Z, et al. TyG index performs better than HOMA-IR in Chinese type 2 diabetes mellitus with a BMI < 35 kg/m2: a hyperglycemic clamp validated study. Med  2022;58(7):876.
57.
Yang CD, Pan WQ, Feng S, Quan JW, Chen JW, Shu XY, et al. Insulin resistance is Associated With Heart failure with recovered ejection fraction in patients without diabetes. J Am Heart Association. 2022;11(19):e026184.CrossRef
58.
Khalaji A, Behnoush AH, Saeedian B, Khanmohammadi S, Shokri Varniab Z, Peiman S. Endocan in prediabetes, diabetes, and diabetes-related complications: a systematic review and meta-analysis. Diabetol Metab Syndr. 2023;15(1):102.PubMedPubMedCentralCrossRef
59.
Nishida K, Otsu K. Inflammation and metabolic cardiomyopathy. Cardiovasc Res. 2017;113(4):389–98.PubMedCrossRef
Metadata
Title
Triglyceride-glucose index and heart failure: a systematic review and meta-analysis
Authors
Amirmohammad Khalaji
Amir Hossein Behnoush
Shaghayegh Khanmohammadi
Kimiya Ghanbari Mardasi
Sourena Sharifkashani
Amirhossein Sahebkar
Caterina Vinciguerra
Alessandro Cannavo
Publication date
01-12-2023
Publisher
BioMed Central
Published in
Cardiovascular Diabetology / Issue 1/2023
Electronic ISSN: 1475-2840
DOI
https://doi.org/10.1186/s12933-023-01973-7

Other articles of this Issue 1/2023

Cardiovascular Diabetology 1/2023 Go to the issue

Research

Dysregulation of hypoxia-inducible factor 1α in the sympathetic nervous system accelerates diabetic cardiomyopathy

Research

Timing of SGLT2i initiation after acute myocardial infarction

Research

Impact of type 2 diabetes on life expectancy and role of kidney disease among inpatients with heart failure in Switzerland: an ambispective cohort study

Research

Sex-specific associations between adipokine profiles and carotid-intima media thickness in the Cameron County Hispanic Cohort (CCHC)

Research

Effects of diabetes mellitus on left ventricular function and deformation in patients with restrictive cardiomyopathies: a 3.0T CMR feature tracking study

Research

Inflammation and oxidative stress markers in type 2 diabetes patients with Advanced Carotid atherosclerosis
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Image Credits